Overview

Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer

Status:
Not yet recruiting

Trial end date:
2030-03-01

Target enrollment:

Participant gender:

Summary

It is a phase III trial to explore the efficacy and safety of utidelone plus capecitabine versus taxane plus capecitabine in HER2-negative locally advanced or metastatic breast cancer and the differences of metronomic capecitabine and intermittent capecitabine in combination chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Sun Yat-sen University

Collaborator:

Chengdu Biostar

Treatments:

Capecitabine
Taxane